During the past decade, McLaren-Greater Lansing conducted 23 clinical trials. In the 10-year time frame, 23 clinical trials started and 11 clinical trials were completed, i.e. on average, 47.8% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 6 clinical trials were completed. i.e. 120% of trials that started reached the finish line.

Out of the total clinical trials conducted in "McLaren-Greater Lansing" #1 sponsor was "SWOG Cancer Research Network" with 9 trials, followed by "Alliance for Clinical Trials in Oncology" with 6 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 3 trials sponsored, "NRG Oncology" with 3 trials sponsored and "Abbott Medical Devices" with 3 trials sponsored. Other sponsors include 11 different institutions and companies that sponsored additional 18 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "McLaren-Greater Lansing" #1 collaborator was "National Cancer Institute (NCI)" with 21 trials as a collaborator, "Canadian Cancer Trials Group" with 3 trials as a collaborator, "Bayer" with 1 trials as a collaborator, "Blue Cross Blue Shield of Michigan Foundation" with 1 trials as a collaborator and "Cancer Prevention Pharmaceuticals, Inc." with 1 trials as a collaborator. Other collaborators include 7 different institutions and companies that were collaborators in the rest 17 trials.

According to Clinical.Site data, the most researched conditions in "McLaren-Greater Lansing" are "Coronary Artery Disease" (6 trials), "Estrogen Receptor Negative" (3 trials), "HER2/Neu Negative" (3 trials), "Progesterone Receptor Negative" (3 trials) and "Stage IIA Breast Cancer" (3 trials). Many other conditions were trialed in "McLaren-Greater Lansing" in a lesser frequency.

Most popular intervention types in "McLaren-Greater Lansing" are "Drug" (25 trials), "Other" (16 trials), "Device" (7 trials), "Biological" (4 trials) and "Procedure" (3 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (7 trials), "Quality-of-Life Assessment" (5 trials), "Carboplatin" (3 trials), "Placebo" (3 trials) and "Questionnaire Administration" (3 trials). Other intervention names were less common.

The vast majority of trials in "McLaren-Greater Lansing" are 33 trials for "All" genders, 3 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "McLaren-Greater Lansing". undefined are not yet recruiting, 4 are recruiting, 13 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 18 completed trials in McLaren-Greater Lansing, 1 suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in McLaren-Greater Lansing, 2 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 6 trials that are defined as “Not Applicable".